LWA
ARCT icon

Lenox Wealth Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Lenox Wealth Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-86
Closed -$4K – 261
2015
Q4 		$4K Buy
+86
New +$3.87K ﹤0.01% 240

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Lenox Wealth Advisors's ARCT Position: Q1 2016 in Review

Lenox Wealth Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2016, closing a stake of 86 shares — an estimated $4K sold.

Lenox Wealth Advisors first reported a position in ARCT in Q4 2015 and held it in 1 quarter. The position peaked at $4K in Q4 2015. 46 funds tracked by Wall St. Rank hold ARCT as of Q1 2016.

  • Lenox Wealth Advisors reported no remaining Arcturus Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Lenox Wealth Advisors sold 86 Arcturus Therapeutics shares in Q1 2016, an estimated $4K.
  • Lenox Wealth Advisors first reported a position in Arcturus Therapeutics in Q4 2015 and held it in 1 quarter.
  • Lenox Wealth Advisors's Arcturus Therapeutics position peaked at $4K in Q4 2015.
  • 46 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2016.

Based on Lenox Wealth Advisors's 13F filing for Q1 2016, filed 11 Apr 2016.